Bio Path reported $-8.49M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Baxter International USD 6.5B 296M Sep/2026
Bio Path USD -8.49M 482K Mar/2026
Cipla INR 353.96B 9.64B Sep/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 88.73M 6.62M Jun/2026
CSL USD 18.66B 2.75B Dec/2025
Grifols EUR 6.21B 133.12M Dec/2025
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026